Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
The non-psychoactive phytocannabinoid cannabidiol (CBD) attenuates pro-inflammatory mediators, T cell infiltration, and thermal sensitivity following spinal cord injury in mice.
Li H, Kong W, Chambers CR, Yu D, Ganea D, Tuma RF, Ward SJ.
Cell Immunol. 2018 Jul;329:1-9. doi: 10.1016/j.cellimm.2018.02.016. Epub 2018 Mar 8.
Similar articles
[Delta-9-tetrahydrocannabinol-cannabidiol in the treatment of spasticity in chronic spinal cord injury: a clinical experience].
Grao-Castellote C, Torralba-Collados F, Gonzalez LM, Giner-Pascual M.
Rev Neurol. 2017 Oct 1;65(7):295-302. Spanish.
Cannabidiol administration reduces sublesional cancellous bone loss in rats with severe spinal cord injury.
Li D, Lin Z, Meng Q, Wang K, Wu J, Yan H.
Eur J Pharmacol. 2017 Aug 15;809:13-19. doi: 10.1016/j.ejphar.2017.05.011. Epub 2017 May 4.
A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis.
Giacoppo S, Galuppo M, Pollastro F, Grassi G, Bramanti P, Mazzon E.
Daru. 2015 Oct 21;23:48. doi: 10.1186/s40199-015-0131-8.
Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice.
Rahimi A, Faizi M, Talebi F, Noorbakhsh F, Kahrizi F, Naderi N.
Neuroscience. 2015 Apr 2;290:279-87. doi: 10.1016/j.neuroscience.2015.01.030. Epub 2015 Jan 28.
Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity nervous pathways.
Centonze D.
Eur Neurol. 2014;72 Suppl 1:6-8. doi: 10.1159/000367615. Epub 2014 Sep 26.
Cannabidiol-treated rats exhibited higher motor score after cryogenic spinal cord injury.
Kwiatkoski M, Guimarães FS, Del-Bel E.
Neurotox Res. 2012 Apr;21(3):271-80. doi: 10.1007/s12640-011-9273-8. Epub 2011 Sep 14.
Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice.
Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R, Ben-Nun A, Juknat A, Vogel Z.
Br J Pharmacol. 2011 Aug;163(7):1507-19. doi: 10.1111/j.1476-5381.2011.01379.x.
Lack of positive allosteric modulation of mutated alpha(1)S267I glycine receptors by cannabinoids.
Foadi N, Leuwer M, Demir R, Dengler R, Buchholz V, de la Roche J, Karst M, Haeseler G, Ahrens J.
Naunyn Schmiedebergs Arch Pharmacol. 2010 May;381(5):477-82. doi: 10.1007/s00210-010-0506-9. Epub 2010 Mar 26.
The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-Beta glycine receptor function.
Ahrens J, Demir R, Leuwer M, de la Roche J, Krampfl K, Foadi N, Karst M, Haeseler G.
Pharmacology. 2009;83(4):217-22. doi: 10.1159/000201556. Epub 2009 Feb 10. Erratum in: Pharmacology. 2010;86(5-6):344.
GW-1000. GW Pharmaceuticals.
Smith PF.
Curr Opin Investig Drugs. 2004 Jul;5(7):748-54.
Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
[No authors listed]
Drugs R D. 2003;4(5):306-9. Review.
Therapeutic potential of cannabinoids in CNS disease.
Croxford JL.
CNS Drugs. 2003;17(3):179-202. Review.
A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.
Wade DT, Robson P, House H, Makela P, Aram J.
Clin Rehabil. 2003 Feb;17(1):21-9.
Filters: Manage Filters